

## VIEWPOINT

# A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection

## Illness Beyond Acute Infection and Public Health Implications

**S. Deblina Datta, MD**  
COVID-19 Response,  
US Centers for Disease  
Control and  
Prevention, Atlanta,  
Georgia.

**Amish Talwar, MD,  
MPH**  
COVID-19 Response,  
US Centers for Disease  
Control and  
Prevention, Atlanta,  
Georgia.

**James T. Lee, MD, MSc**  
COVID-19 Response,  
US Centers for Disease  
Control and  
Prevention, Atlanta,  
Georgia; and Epidemic  
Intelligence Service,  
US Centers for Disease  
Control and  
Prevention, Atlanta,  
Georgia.

**Corresponding  
Author:** Amish  
Talwar, MD, MPH,  
US Centers for Disease  
Control and  
Prevention, 1600  
Clifton Rd NE,  
Mailstop H21-3,  
Atlanta, GA 30329  
([atalwar@cdc.gov](mailto:atalwar@cdc.gov)).

[jama.com](http://jama.com)

**Although much of the response** to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has focused on acute coronavirus disease 2019 (COVID-19) illness, accumulating evidence demonstrates morbidity beyond acute SARS-CoV-2 infection.<sup>1-4</sup> At least 2 other periods of illness appear to be temporally associated with SARS-CoV-2 infection: a rare postacute hyperinflammatory illness and late inflammatory and virological sequelae. These 3 illness periods not only define the temporal course of SARS-CoV-2 infection at the population level but also capture distinct phases of host-viral interaction.

A theoretical framework describing illness periods of SARS-CoV-2 infection (including clinical presentations and timing of onset), their pathophysiological underpinnings, and associated key laboratory findings may contribute to a more inclusive and ordered

### At least 2 other periods of illness appear to be temporally associated with SARS-CoV-2 infection: a rare postacute hyperinflammatory illness and late inflammatory and virological sequelae.

understanding of the natural history of SARS-CoV-2 infection and enhance research efforts. Within the proposed framework, a patient may experience any combination of these illnesses or may have asymptomatic infection without illness (Figure).

#### Acute Infection or COVID-19

Acute infection or COVID-19 represents the initial illness period following SARS-CoV-2 infection and is the best characterized of the 3 illness periods. The onset of COVID-19 signs or symptoms (eg, cough, fever, dyspnea) is associated with viral replication and initial host immune response.<sup>5</sup> Asymptomatic SARS-CoV-2 infection may occur in 3% to 67% of infected patients<sup>6</sup> and can be followed by the other 2 illness periods; therefore, symptomatic infection is not a necessary precursor to later illnesses. The duration of acute infection is typically days to weeks.<sup>7</sup> Key laboratory findings include positive test results for SARS-CoV-2 components (ie, positive reverse transcriptase-polymerase chain reaction [RT-PCR] or antigen tests) followed by seroconversion (ie, positive for IgM or IgG) for the majority of patients within 2 weeks following initial symptom onset.<sup>8</sup>

#### Postacute Hyperinflammatory Illness

A rare multisystem inflammatory illness has been observed in both children and adults following acute

SARS-CoV-2 infection.<sup>1,2</sup> Distinct from early inflammation resulting from viral replication and cell death, hyperinflammation can occur in organ systems distinct from those affected during COVID-19 and can begin after host clearance of SARS-CoV-2 infection. The pathophysiology of this illness, termed *multisystem inflammatory syndrome* in children (MIS-C) and in adults (MIS-A), remains under investigation but likely reflects a dysregulated host immune response.<sup>1,2</sup> MIS-C and MIS-A manifest approximately 2 to 5 weeks after onset of SARS-CoV-2 infection.<sup>1,2</sup>

Patients may have prominent cardiovascular and gastrointestinal manifestations as well as dermatological and mucocutaneous manifestations similar to the hyperinflammatory condition Kawasaki disease.<sup>1,2</sup> Laboratory testing may reveal elevated inflammatory markers

(eg, C-reactive protein and ferritin levels), coagulopathy (eg, D-dimer), and elevated cardiac markers (eg, troponin level).<sup>1,2</sup> Patients with MIS-C and MIS-A are found to be almost universally antibody positive, but many have negative RT-PCR test results for SARS-CoV-2 infection.<sup>1,2</sup> The extent of MIS-A has not been as well-characterized as MIS-C,

likely because adults often have more comorbidities and more severe COVID-19 illness compared with children.<sup>9</sup> The more complex and prolonged course of illness makes it difficult to identify hyperinflammation as a distinct process from acute infection in adults.

#### Late Inflammatory and Virological Sequelae

Late sequelae have been observed for several infectious diseases, including Lyme disease, syphilis, and Ebola. The etiologies of such late sequelae are not all well characterized, but may reflect organ involvement during the acute infection period, manifestations of a long-term hyperinflammatory state, physical debilitation or psychological sequelae following a long or difficult disease course, or ongoing viral activity associated with a host viral reservoir.

Understanding of late sequelae of SARS-CoV-2 infection is still limited, particularly because early reports have been selected case series without any comparison groups. In one study, 87% of 143 previously hospitalized patients had 1 or more persistent symptoms (including fatigue, dyspnea, joint pain, and chest pain) 60 days after the date of initial COVID-19 symptom onset.<sup>3</sup> These late sequelae do not appear to be necessarily limited to persons requiring hospitalization. However, very limited data are available at the population level about the extent of late sequelae.

**Figure. Proposed Population-Based Framework for Symptomatic SARS-CoV-2 Infection<sup>a</sup>**

Symptom onset	Week 2	Week 4
<b>Acute infection (COVID-19)</b>	<b>Postacute hyperinflammatory illness</b>	<b>Late sequelae</b>
Characterization		
Active viral replication and initial host response	Dysregulated host response	Pathophysiological pathways proposed but unproven
Clinical presentation		
Fever, cough, dyspnea, myalgia, headache, sore throat, diarrhea, nausea, vomiting, anosmia, dysgeusia, abdominal pain	Gastrointestinal, cardiovascular, dermatologic/mucocutaneous, respiratory, neurological, musculoskeletal symptoms	Cardiovascular, pulmonary, neurological, psychological manifestations
Laboratory tests		
Viral test (+) Antibody (+) after 2 wk	Viral test (+/-) Antibody (+) after 2 wk	Viral test and antibody profile uncharacterized

COVID-19 indicates coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup> Population-based framework refers to the fact that these illnesses are observed at the population level and not necessarily in any given individual.

Some reports have described late sequelae involving cardiovascular, pulmonary, neurological, and psychological manifestations.<sup>4</sup> The etiology of these late sequelae remains uncertain.

The third illness period in this proposed framework comprises late sequelae of SARS-CoV-2 infection attributable to either an inflammatory or viral host response that occur approximately 4 weeks after initial infection and continue for an as yet uncharacterized duration. Interest in late sequelae continues to increase as numerous reports detailing the plight of patients characterized as SARS-CoV-2 “long haulers” continue to emerge. At present, there is limited information about the underlying pathophysiology, disease duration, or long-term prognosis of affected persons. It is possible that the late sequelae of COVID-19 represent multiple syndromes resulting from distinct pathophysiological processes along the spectrum of disease.

### Public Health Significance

This proposed framework will be further refined with accumulating evidence, especially regarding the postacute hyperinflammatory phase and late sequelae. However, this framework may provide a useful approach to understanding the extent of morbidity and mortality from SARS-CoV-2 infection and may have important implications for public health surveillance, clinical research, future treatments, and health services planning. Acute COVID-19 is only a subset of the morbidity and mortality attributable to SARS-CoV-2-associated disease. Until this time, and rightfully so, most efforts have centered on prevention and treatment of acute illness. However, future medical and social interventions must consider the full spectrum of disease due to SARS-CoV-2, the cost and consequences of which extend beyond initial case diagnosis and treatment.

### ARTICLE INFORMATION

**Published Online:** November 18, 2020.  
doi:10.1001/jama.2020.22717

**Conflict of Interest Disclosures:** None reported.

**Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.

**Additional Contributions:** We recognize the following members of the US Centers for Disease Control and Prevention COVID-19 clinical team: Michael Melgar, MD, Ermias D. Belay, MD, Kevin R. Clarke, MD, John Iskander, MD, MPH, and John T. Brooks, MD.

### REFERENCES

1. Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. *J Pediatr*. Published online August 5, 2020. doi:10.1016/j.jpeds.2020.08.003

2. Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 Infection—United Kingdom and United States, March–August 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(40):1450–1456. doi:10.15585/mmwr.mm6940e1

3. Carfi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. *JAMA*. 2020;324(6):603–605. doi:10.1001/jama.2020.12603

4. Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. *JAMA*. 2020;324(17):1723–1724. doi:10.1001/jama.2020.19719

5. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA*. 2020;324(8):782–793. doi:10.1001/jama.2020.12839

6. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of

asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. *PLoS Med*. 2020;17(9):e1003346. doi:10.1371/journal.pmed.1003346

7. Tenforde MW, Billig Rose E, Lindsell CJ, et al; CDC COVID-19 Response Team. Characteristics of adult outpatients and inpatients with COVID-19—11 academic medical centers, United States, March–May 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(26):841–846. doi:10.15585/mmwr.mm6926e3

8. Young BE, Ong SWX, Ng LFP, et al; Singapore 2019 Novel Coronavirus Outbreak Research team. Viral dynamics and immune correlates of COVID-19 disease severity. *Clin Infect Dis*. Published online August 28, 2020. doi:10.1093/cid/ciaa1280

9. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(24):759–765. doi:10.15585/mmwr.mm6924e2